Fecal transplant for advanced liver cancer after treatment stops working
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a fecal transplant (a procedure that replaces the bacteria in your gut) can help people with advanced liver cancer whose current treatment has stopped working. It may help boost your immune system to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced liver cancer that cannot be removed by surgery and has not responded to standard treatment.
- Your liver function is at a certain level (Child-Pugh class A or B with a score of 7 or less).
- You have at least one tumor that can be measured on imaging scans.
- You are able to carry out light activities (performance status 0-2).
- You have not taken antibiotics in the last 4 weeks, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
This trial tests whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help your liver cancer become sensitive again to treatment that has stopped working. It may help reverse drug resistance and improve outcomes for people with advanced liver cancer.
This trial tests whether transplanting healthy stool bacteria into your gut can help your own immune system fight liver cancer that has stopped responding to the standard first combination treatment (atezolizumab + bevacizumab). It is for patients whose liver cancer has started growing quickly despite that treatment.
This trial tests combining a fecal transplant (healthy donor bacteria) with two drugs—QL1706 (an immunotherapy) and bevacizumab (a blood vessel blocker)—for people with advanced liver cancer that hasn't been treated before. The goal is to see if this combination can shrink tumors or slow their growth.
This trial studies fecal microbiota transplantation (a transfer of healthy gut bacteria from a donor) to help people with worsening liver failure. It may help by changing gut bacteria, which can affect complications like confusion, fluid buildup, infections, and kidney problems.
This trial studies how the gut (your digestive system) affects how well immunotherapy works for advanced liver cancer. You'll have a colonoscopy (a test to look inside your bowel) and provide samples, which could help doctors improve treatment for you and others.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.